Clinical Trial Detail

NCT ID NCT04446117
Title Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)
Recruitment Recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Exelixis
Indications

prostate adenocarcinoma

Therapies

Enzalutamide

Atezolizumab + Cabozantinib

Abiraterone + Prednisone

Age Groups: adult senior

No variant requirements are available.